Aurinia Acquires Kezar Life Sciences
In Plain English
Kezar Life Sciences is involved in a merger arbitrage transaction. This is actively in progress.
Corporate event in progress — monitor for updates
Deal Progress
RUMORED
ANNOUNCED
PENDING
ACTIVE
COMPLETED
Parent Company
Kezar Life Sciences
KZR
Biotechnology
Announced
Mar 30, 2026
4w ago
Expected
TBD
Market Cap
Not disclosed
Deal Value
$50.93M
Summary
Aurinia Pharmaceuticals (AUPH) to acquire Kezar Life Sciences in a $50.93 million deal.
Deal Flow Timeline
Key milestones from announcement to expected completion
Deal Announced
2026-03-30
COMPLETEDRegulatory Filing
COMPLETEDRegulatory Approval
COMPLETEDShareholder Vote
COMPLETEDExpected Close
UPCOMINGDeal Announced
COMPLETEDInitial public announcement of the transaction.
2026-03-30
Regulatory Filing
COMPLETEDHSR / antitrust filing submitted to relevant authorities.
Regulatory Approval
COMPLETEDAntitrust clearance received from DOJ/FTC/EU/CFIUS.
Shareholder Vote
COMPLETEDTarget and/or acquirer shareholder approval.
Expected Close
UPCOMINGTransaction expected to close and complete.